Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Rexulti Makes Mark in Japan PIII Study for Alzheimer’s Agitation: Otsuka
Otsuka Pharmaceutical said on June 27 that its atypical antipsychotic Rexulti (brexpiprazole) hit the main goal in a domestic PIII trial targeting an additional indication of agitation associated with Alzheimer’s dementia. The company plans to seek the drug’s label expansion…
To read the full story
Related Article
- Rexulti Snags US Approval for Alzheimer’s Agitation: Otsuka/Lundbeck
May 12, 2023
- Rexulti Backed by FDA Advisors for Alzheimer’s Agitation: Otsuka/Lundbeck
April 18, 2023
- US FDA Accepts Rexulti sNDA for Alzheimer’s Agitation: Otsuka/Lundbeck
January 11, 2023
- Brexpiprazole Cuts Alzheimer’s Agitation in PIII Study: Otsuka/Lundbeck
June 28, 2022
- Otsuka, Lundbeck to Carry On Multinational PIII of Brexpiprazole for Agitation in Alzheimer’s
April 14, 2021
BUSINESS
- Lilly Confirms Orforglipron Diabetes Filings in US, Japan
August 7, 2026
- Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
- Inrebic Expands First-Line Treatment Options for Myelofibrosis: Expert
August 7, 2026
- Meiji Pharma Drops Hiyasta Development in B-Cell NHL
August 7, 2026
- AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…